98%
921
2 minutes
20
Duchenne Muscular Dystrophy (DMD) is a prevalent fatal genetic disorder, and heart failure is the leading cause of mortality. Peak left ventricular (LV) circumferential strain (E), twist, and circumferential-longitudinal shear angle (θ) are promising biomarkers for the improved and early diagnosis of incipient heart failure. Our goals were as follows: 1) to characterize a spectrum of functional and rotational LV biomarkers in boys with DMD compared with healthy age-matched controls; and 2) to identify LV biomarkers of early cardiomyopathy in the absence of abnormal LVEF or LGE. Boys with DMD ( = 43) and age-matched healthy volunteers ( = 16) were prospectively enrolled and underwent a 3T CMR exam after obtaining informed consent. Breath-held MRI tagging was used to estimate left ventricular E at the mid-ventricular level as well as the twist, torsion, and θ between basal and apical LV short-axis slices. A two-tailed -test with unequal variance was used to test group-wise differences. Multiple comparisons were performed with Holm-Sidak post hoc correction. Multiple-regression analysis was used to test for correlations among biomarkers. A binomial logistic regression model assessed each biomarker's ability to distinguish the following: (1) healthy volunteers vs. DMD patients, (2) healthy volunteers vs. LGE(-) DMD patients, and (3) LGE(-) DMD patients vs. LGE(+) DMD patients. There was a significant impairment in the peak mid-wall E [-17.0 ± 4.2% vs. -19.5 ± 1.9%, < 7.8 × 10], peak LV twist (10.4 ± 4.3° vs. 15.6 ± 3.1°, < 8.1 × 10), and peak LV torsion (2.03 ± 0.82°/mm vs. 2.8 ± 0.5°/mm, < 2.6 × 10) of LGE(-) DMD patients when compared to healthy volunteers. There was a further significant reduction in the E, twist, torsion, and θ for LGE(+) DMD patients when compared to LGE(-) DMD patients. In the LGE(+) DMD patients, age significantly correlated with LVEF ( = 0.42, = 9 × 10), peak mid-wall E ( = 0.27, = 0.046), peak LV Twist ( = 0.24, = 0.06), peak LV torsion ( = 0.28, = 0.04), and peak LV θ ( = 0.23, = 0.07). In the LGE(-) DMD patients, only the peak mid-wall E was significantly correlated with age ( = 0.25, = 0.006). The peak LV twist outperformed the peak mid-wall LV E and EF in distinguishing DMD patients from healthy volunteer groups (AUC = 0.88, 0.80, and 0.72), as well as in distinguishing LGE(-) DMD patients from healthy volunteers (AUC = 0.83, 0.74, and 0.62). The peak LV twist and peak mid-wall LV E performed similarly in distinguishing the LGE(-) and LGE(+) DMD cohorts (AUC = 0.74, 0.77, and 0.79). The peak mid-wall LV E, peak LV twist, peak LV torsion, and peak LV θ were significantly impaired in advance of the decreased LVEF and the development of focal myocardial fibrosis in boys with DMD and therefore were apparent prior to significant irreversible injury.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11817951 | PMC |
http://dx.doi.org/10.3390/diagnostics15030326 | DOI Listing |
Skelet Muscle
September 2025
Sorbonne Université, Inserm, Institut de Myologie, Centre de Recherche en Myologie, Paris, France.
Duchenne muscular dystrophy (DMD) is a severe, progressive genetic disorder caused by mutations in the DMD gene, resulting in the absence of dystrophin-a key structural protein at the sarcolemma. As the disease progresses, cardiac involvement becomes a leading cause of morbidity and mortality. By adolescence or early adulthood, many patients develop dilated cardiomyopathy and arrhythmias.
View Article and Find Full Text PDFJ Neurochem
September 2025
Department of Biology and Biotechnologies "Charles Darwin", Sapienza University of Rome, Rome, Italy.
Patients with Duchenne muscular dystrophy (DMD) may experience neurobehavioral and cognitive concerns, including psychiatric symptoms, due to the absence of full-length dystrophin (Dp427), frequently accompanied by deficiencies in shorter isoforms. The lack of dystrophin affects neurophysiological processes from the uterine phase, impacting neural circuitry in brain regions such as the prefrontal cortex, hippocampus, and cerebellum. This leads to reduced inhibitory GABAergic transmission and altered hippocampal glutamatergic signaling.
View Article and Find Full Text PDFAm J Phys Med Rehabil
August 2025
Center for Neuromuscular Disease Child Health and Development, National Hospital Organization, Hokkaido, Medical Center, Japan.
Introduction: Duchenne muscular dystrophy (DMD) management often results in tracheostomies or palliative care deaths.
Methods: Two centers, A in the U.S.
Zhonghua Nei Ke Za Zhi
September 2025
Duchenne muscular dystrophy (DMD) is an X-linked recessive myopathy caused by mutations in the dystrophin gene, which is divided into presymptomatic, early ambulatory, late ambulatory, early non-ambulatory, and late non-ambulatory stages according to its disease progression. Some patients experience non-progressive cognitive developmental delays in the presymptomatic stage. DMD patients gradually develop osteoporosis, cardiomyopathy, decreased respiratory function, delayed puberty, and gastrointestinal symptoms as the disease progresses.
View Article and Find Full Text PDFNeurol Genet
October 2025
Carleton University, Ottawa, Canada.
Background And Objectives: Understanding the reliability of outcomes used in clinical care and trials is important to delineate intervention-induced change from random variability. Reliability, sensitivity, and clinical meaningfulness of change are all key aspects of choosing the most appropriate outcome measure for a clinical trial. Common outcome measures to monitor progression and treatment effect in Duchenne muscular dystrophy (DMD) include measures of strength (myometry) and motor function tests: stand from supine velocity (STANDV), North Star Ambulatory Assessment (NSAA), 6-minute walk distance (6MWD), 10-m run/walk (RWV), and 4-stair climb velocity (CLIMBV).
View Article and Find Full Text PDF